Developer docs
API playgroundTry for free, no card

Search company profiles

Piramal Pharma Solutions

Full company profile

uuid00057up

Namestring
Piramal Pharma Solutions
Legal namestring
Piramal Enterprises Limited
Company typeenum
Private
Founded yearint
1990
Descriptiontext

Piramal Pharma Solutions is a global Contract Development and Manufacturing Organization (CDMO) that provides end-to-end pharmaceutical services across the entire drug lifecycle, from discovery through commercial supply. The company serves pharmaceutical innovators and biotech companies requiring integrated development and manufacturing solutions. Core service offerings include drug discovery (synthetic chemistry, in-vitro biology, DMPK, route scouting), drug substance/API manufacturing (including specialized high-potency APIs, peptides, and hormonal APIs), drug product formulation and manufacturing (oral solids, sterile injectables, liquids, creams, ointments), and Antibody Drug Conjugates supported by the ADCelerate™ integrated platform. Additional capabilities include vaccines and biologics through associate company Yapan Bio, and nutrition solutions. Notable technical assets include proprietary payload-linker manufacturing, isolator-based sterile fill/finish technology, and digital quality tools (eLab, exForms, iAssist, RESOLVE).

The company operates approximately 15 global facilities across North America (US, Canada), Europe (UK), and Asia (India, China), with a commercial presence in over 100 countries. Manufacturing scale includes 245+ reactors, over 750 kL volumetric capacity, 4.5 billion OSD units/year, and 1,500+ ADC batches delivered to date. The CDMO segment accounts for 55% of parent company Piramal Pharma Limited's FY2026 revenue of 8,869 Crore Rupees, with 66% of sales generated from regulated markets. The company employs 7,285+ people globally (zero workplace fatalities for five consecutive years) and serves 500+ international clients.

Business model is contract-based B2B CDMO services with quote-based pricing not publicly disclosed. Go-to-market is direct enterprise sales with Integrated Program Managers assigned as single points of contact for cross-geography project coordination. The company has passed 365+ regulatory inspections including USFDA, EU GMP, MHRA, PMDA, and ANVISA with zero OAI observations, and holds a Net Promoter Score of 55 for FY2025. Piramal Pharma Solutions is a wholly-owned subsidiary of Piramal Pharma Limited (publicly listed in India), which is part of the Piramal Group conglomerate.

Short descriptiontext

Piramal Pharma Solutions is a global B2B CDMO providing end-to-end pharmaceutical development and manufacturing services, from drug discovery to commercial supply, serving pharmaceutical innovators and biotech companies across 15+ facilities in North America, Europe, and Asia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersLexington, United States
HQ citystring
Lexington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices13 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract pharmaceutical manufacturing, API development services, antibody drug conjugates, sterile injectable fill finish, high potency API manufacturing
Industry1 code
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Contract Development and Manufacturing Organization (CDMO)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Contract Development and Manufacturing (CDMO) Services
TypeProfessional Services
Description

Piramal Pharma Solutions generates revenue through contract development and manufacturing services for pharmaceutical companies. The CDMO segment (Piramal Pharma Solutions division) accounts for 55% of parent company Piramal Pharma Limited's revenue. Services include drug substance manufacturing, drug product manufacturing, and specialized offerings.

prnewswire.com
2API Manufacturing and Sales
TypeOne Time License
Description

Manufacturing and supply of Active Pharmaceutical Ingredients (APIs) including generic APIs, high potency APIs (HPAPIs), peptides, and hormonal APIs across global facilities.

aninews.in
3Drug Product Manufacturing
TypeOne Time License
Description

Clinical and commercial manufacturing of oral solids, sterile injectables, liquids, creams, and ointments with packaging services.

piramalpharmasolutions.com
4Specialized Services
TypeProfessional Services
Description

ADC development and manufacturing, vaccine and biologics manufacturing through associate company Yapan Bio, and nutrition solutions.

piramalpharmasolutions.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 7 records shown
1ADCelerate
Description

Integrated ADC solution that accelerates timelines for developing initial clinical supply of both drug substance and drug product

piramalpharmasolutions.com
+6 more records
Core offering1 text field

Piramal Pharma Solutions is a global Contract Development and Manufacturing Organization (CDMO) that provides end-to-end pharmaceutical services across the drug lifecycle, from discovery through commercialization. Core offerings include drug discovery services (synthetic chemistry, in-vitro biology, DMPK), drug substance/API development and manufacturing (including high-potency, peptides, hormonal, and controlled substances), drug product formulation and manufacturing (oral solids, liquids, creams, ointments, sterile injectables), and specialized offerings in antibody drug conjugates (via the ADCelerate platform), vaccines and biologics, and nutrition solutions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Zero OAI observations across all USFDA inspections
+4 more records
Product overview1 text field

Piramal Pharma Solutions is a global Contract Development and Manufacturing Organization (CDMO) offering end-to-end pharmaceutical services spanning the entire drug lifecycle. The company operates as a unified platform combining Drug Discovery Services (synthetic chemistry, in-vitro biology, DMPK, route scouting), Drug Substance/API Manufacturing (including specialized HPAPI, peptides, and hormonal APIs), Drug Product services (formulation development, oral solids, sterile injectables), and Antibody Drug Conjugates (supported by the ADCelerate™ platform). Additional specialized offerings include Vaccines and Biologics through associate company Yapan Bio, and Nutrition Solutions. The portfolio also includes digital quality tools (eLab, exForms, iAssist, RESOLVE) and the Science Collective expert team. Services are delivered through 15 global facilities across North America, Europe, and Asia.

Product and service11 records
1Drug Discovery Services
CategoryDrug Discovery Services
Description

Comprehensive drug discovery services including synthetic chemistry, in-vitro biology, in-vitro ADME, route scouting, analytical support, and non-GMP kilo lab services for pharmaceutical, biotech, and academic customers.

2Drug Substance (API Development & Manufacturing)
CategoryAPI Development and Manufacturing
Description

End-to-end active pharmaceutical ingredient (API) development and manufacturing services including route scouting, process and analytical development, pre-GMP scale-up, and pre-clinical, clinical, and commercial supply for pharmaceutical innovators.

3Generic APIs
CategoryAPI Manufacturing
Description

Manufacturing and supply of generic active pharmaceutical ingredients for commercial pharmaceutical products across global facilities.

4Special APIs (HPAPI, Peptides, Hormonal, Controlled Substances)
CategorySpecialty API Manufacturing
Description

Specialized API manufacturing capabilities for high potency APIs (HPAPI), peptides, hormonal APIs, and controlled substances with advanced containment facilities such as high-potency manufacturing with OEL down to 0.01 µg/m³.

5Drug Product (Formulation Development & Manufacturing)
CategoryDrug Product Development and Manufacturing
Description

Formulation development and commercial manufacturing of oral solids, liquids, creams, ointments, sterile injectables, controlled substances, potent OSDs, and hormonal formulations for clinical and commercial supply.

6Sterile Injectables
CategorySterile Injectable Manufacturing
Description

Sterile injectable manufacturing including formulation development, fill-finish, lyophilization, and aseptic processing with Grade A isolator-based technology for potent compounds, cytotoxics, hormones, and steroids.

7Antibody Drug Conjugates (ADCs)
CategoryBiological Drug Conjugate Manufacturing
Description

End-to-end antibody-drug conjugate development and manufacturing including payload-linker development, conjugation, and fill-finish services across Grangemouth (UK), Riverview (USA), and Lexington (USA) sites. First FDA-approved ADC CDMO with 20+ years of experience and 1,500+ ADC batches manufactured.

8ADCelerate
CategoryADC Integrated Platform
Description

Proprietary integrated ADC solution platform that accelerates timelines for developing initial clinical supply of both drug substance and drug product, covering preclinical to commercial-scale manufacturing via the ADCelerate program.

9Peptides
CategoryPeptide API Manufacturing
Description

End-to-end peptide API development and manufacturing services including both solution phase and solid phase synthesis capabilities, regulatory filings, and characterization for commercial supply.

10Vaccines and Biologics
CategoryBiologics and Vaccine Manufacturing
Description

Development and manufacturing services for vaccines, gene therapy, monoclonal antibodies, and other complex biologics up to 1,000L scale, delivered through associate company Yapan Bio at the Hyderabad facility with BSL-2+ containment.

11Nutrition Solutions
CategoryNutrition and Skincare Ingredients
Description

Comprehensive nutrition solutions including human nutrition premixes (vitamin mineral, fortification, customized), animal nutrition products (Nicomix vitamin premix, liquid feed supplements), skincare ingredients (MaxReti retinol products), and food fortification programs.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-18
Description

Manufacturing and supply agreement for Sofdra (sofpironium bromide), the first FDA-approved new chemical entity for treating primary axillary hyperhidrosis. PPS will perform development and validation at Riverview, Michigan with potential dual-source production at Aurora, Canada facility to provide supply chain redundancy and cost efficiencies. Partnership expected to significantly reduce Botanix's cost of goods sold while ensuring consistent patient access.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-16
Description

Strategic collaboration to support ADC development and manufacturing. Piramal will refer ADC manufacturing customers to Ajinomoto's AJICAP technology platform while Ajinomoto will refer customers to Piramal for CDMO services. Companies entered Material Transfer Agreement enabling technology transfer for Piramal to manufacture AJICAP-based products. Combines Ajinomoto's site-specific conjugation technology with Piramal's clinical and commercial ADC GMP manufacturing expertise.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2025-10-30
Description

Formalized partnership through Memorandum of Understanding to expand bioconjugate capabilities and ADC development services. Agreement involves exploring licensing of IntoCell's drug-linker technologies and offering contract research and manufacturing services.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Associate company providing biologics and vaccine development and manufacturing services. Yapan Bio specializes in process development, scale-up, and GMP-compliant manufacturing of vaccines, gene therapy, monoclonal antibodies, and other complex biologics. Piramal leverages this partnership to offer integrated large molecule services.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

One of the largest pure-play CDMOs globally, offering integrated drug substance, drug product, biologics, and ADC capabilities. Direct competitor to Piramal across formulation, fill-finish, and biologics CDMO services.

TypeDirect peer
Description

Global CDMO leader in biologics, small molecules, and cell & gene therapies. Comparable to Piramal in small-molecule API manufacturing and overlapping in sterile fill-finish and biologics CDMO.

TypeBroad incumbent
Description

Operates a large CDMO business via Patheon. Broader portfolio than Piramal but directly competes across API, drug product, and sterile injectable contract manufacturing.

TypeDirect peer
Description

Major biologics CDMO with large-scale mammalian cell culture capacity. Overlaps with Piramal/Yapan Bio in biologics and vaccine contract manufacturing.

TypeDirect peer
Description

Subsidiary of WuXi AppTec providing integrated API and drug product CDMO services. Direct overlap with Piramal's API manufacturing and formulation development offerings.

6Recipharm
TypeDirect peer
Description

European-headquartered CDMO with strong sterile injectables and oral solids capabilities. Comparable to Piramal in drug product contract manufacturing and HPAPI handling.

7Boehringer Ingelheim BioXcellence
TypeBroad incumbent
Description

Biologics CDMO division of Boehringer Ingelheim, providing process development and commercial manufacturing for biopharmaceuticals. Comparable to Piramal/Yapan Bio's biologics offering.

8Syngene International
TypeRegional player
Description

India-based CRO/CDMO providing discovery, development, and manufacturing services. Strong geographic and capability overlap with Piramal's India-based operations and integrated CDMO model.

TypeBroad incumbent
Description

Eurofins' pharmaceutical CDMO operations offer API development and manufacturing services with global reach, comparable to Piramal's small-molecule API business.

TypeDirect peer
Description

Global CDMO offering integrated API and drug product services including HPAPIs and complex chemistry. Direct mid-tier CDMO competitor with overlapping capabilities to Piramal.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance18 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Piramal Pharma Solutions

Pharmaceutical Contract Development and Manufacturing Organization (CDMO)piramalpharmasolutions.com

Piramal Pharma Solutions is a global B2B CDMO providing end-to-end pharmaceutical development and manufacturing services, from drug discovery to commercial supply, serving pharmaceutical innovators and biotech companies across 15+ facilities in North America, Europe, and Asia.

What Piramal Pharma Solutions does

Piramal Pharma Solutions is a global Contract Development and Manufacturing Organization (CDMO) that provides end-to-end pharmaceutical services across the entire drug lifecycle, from discovery through commercial supply. The company serves pharmaceutical innovators and biotech companies requiring integrated development and manufacturing solutions. Core service offerings include drug discovery (synthetic chemistry, in-vitro biology, DMPK, route scouting), drug substance/API manufacturing (including specialized high-potency APIs, peptides, and hormonal APIs), drug product formulation and manufacturing (oral solids, sterile injectables, liquids, creams, ointments), and Antibody Drug Conjugates supported by the ADCelerate™ integrated platform. Additional capabilities include vaccines and biologics through associate company Yapan Bio, and nutrition solutions. Notable technical assets include proprietary payload-linker manufacturing, isolator-based sterile fill/finish technology, and digital quality tools (eLab, exForms, iAssist, RESOLVE).

The company operates approximately 15 global facilities across North America (US, Canada), Europe (UK), and Asia (India, China), with a commercial presence in over 100 countries. Manufacturing scale includes 245+ reactors, over 750 kL volumetric capacity, 4.5 billion OSD units/year, and 1,500+ ADC batches delivered to date. The CDMO segment accounts for 55% of parent company Piramal Pharma Limited's FY2026 revenue of 8,869 Crore Rupees, with 66% of sales generated from regulated markets. The company employs 7,285+ people globally (zero workplace fatalities for five consecutive years) and serves 500+ international clients.

Business model is contract-based B2B CDMO services with quote-based pricing not publicly disclosed. Go-to-market is direct enterprise sales with Integrated Program Managers assigned as single points of contact for cross-geography project coordination. The company has passed 365+ regulatory inspections including USFDA, EU GMP, MHRA, PMDA, and ANVISA with zero OAI observations, and holds a Net Promoter Score of 55 for FY2025. Piramal Pharma Solutions is a wholly-owned subsidiary of Piramal Pharma Limited (publicly listed in India), which is part of the Piramal Group conglomerate.

Piramal Pharma Solutions firmographics

Firmographics
Name
Piramal Pharma Solutions
Legal name
Piramal Enterprises Limited
Website
https://piramalpharmasolutions.com
Company type
Private
Founded year
1990
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Piramal Pharma Solutions is a global B2B CDMO providing end-to-end pharmaceutical development and manufacturing services, from drug discovery to commercial supply, serving pharmaceutical innovators and biotech companies across 15+ facilities in North America, Europe, and Asia.
Ownership category
akta.pro rank

Piramal Pharma Solutions industry classification

Industry
Product category
Pharmaceutical Contract Development and Manufacturing Organization (CDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Contract pharmaceutical manufacturing
  • API development services
  • Antibody drug conjugates
  • Sterile injectable fill finish
  • High potency API manufacturing

Where Piramal Pharma Solutions is headquartered

Location

Headquarters

HQ city
Lexington
HQ country
United States
HQ region
North America

Offices13 records

Markets served

Piramal Pharma Solutions business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Contract Development and Manufacturing (CDMO) Services: Piramal Pharma Solutions generates revenue through contract development and manufacturing services for pharmaceutical companies. The CDMO segment (Piramal Pharma Solutions division) accounts for 55% of parent company Piramal Pharma Limited's revenue. Services include drug substance manufacturing, drug product manufacturing, and specialized offerings.
  2. API Manufacturing and Sales: Manufacturing and supply of Active Pharmaceutical Ingredients (APIs) including generic APIs, high potency APIs (HPAPIs), peptides, and hormonal APIs across global facilities.
  3. Drug Product Manufacturing: Clinical and commercial manufacturing of oral solids, sterile injectables, liquids, creams, and ointments with packaging services.
  4. Specialized Services: ADC development and manufacturing, vaccine and biologics manufacturing through associate company Yapan Bio, and nutrition solutions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Piramal Pharma Solutions product offering

Product offering

Core offering

Piramal Pharma Solutions is a global Contract Development and Manufacturing Organization (CDMO) that provides end-to-end pharmaceutical services across the drug lifecycle, from discovery through commercialization. Core offerings include drug discovery services (synthetic chemistry, in-vitro biology, DMPK), drug substance/API development and manufacturing (including high-potency, peptides, hormonal, and controlled substances), drug product formulation and manufacturing (oral solids, liquids, creams, ointments, sterile injectables), and specialized offerings in antibody drug conjugates (via the ADCelerate platform), vaccines and biologics, and nutrition solutions.

Product overview

Piramal Pharma Solutions is a global Contract Development and Manufacturing Organization (CDMO) offering end-to-end pharmaceutical services spanning the entire drug lifecycle. The company operates as a unified platform combining Drug Discovery Services (synthetic chemistry, in-vitro biology, DMPK, route scouting), Drug Substance/API Manufacturing (including specialized HPAPI, peptides, and hormonal APIs), Drug Product services (formulation development, oral solids, sterile injectables), and Antibody Drug Conjugates (supported by the ADCelerate™ platform). Additional specialized offerings include Vaccines and Biologics through associate company Yapan Bio, and Nutrition Solutions. The portfolio also includes digital quality tools (eLab, exForms, iAssist, RESOLVE) and the Science Collective expert team. Services are delivered through 15 global facilities across North America, Europe, and Asia.

Differentiator

Problem solved

Functional benefit

Brands

  • ADCelerate: Integrated ADC solution that accelerates timelines for developing initial clinical supply of both drug substance and drug product
  • Nicomix
  • MaxReti
  • RESOLVE
  • eLab
  • exForms
  • iAssist

Products and services

  • Drug Discovery Services Comprehensive drug discovery services including synthetic chemistry, in-vitro biology, in-vitro ADME, route scouting, analytical support, and non-GMP kilo lab services for pharmaceutical, biotech, and academic customers.
  • Drug Substance (API Development & Manufacturing) End-to-end active pharmaceutical ingredient (API) development and manufacturing services including route scouting, process and analytical development, pre-GMP scale-up, and pre-clinical, clinical, and commercial supply for pharmaceutical innovators.
  • Generic APIs Manufacturing and supply of generic active pharmaceutical ingredients for commercial pharmaceutical products across global facilities.
  • Special APIs (HPAPI, Peptides, Hormonal, Controlled Substances) Specialized API manufacturing capabilities for high potency APIs (HPAPI), peptides, hormonal APIs, and controlled substances with advanced containment facilities such as high-potency manufacturing with OEL down to 0.01 µg/m³.
  • Drug Product (Formulation Development & Manufacturing) Formulation development and commercial manufacturing of oral solids, liquids, creams, ointments, sterile injectables, controlled substances, potent OSDs, and hormonal formulations for clinical and commercial supply.
  • Sterile Injectables Sterile injectable manufacturing including formulation development, fill-finish, lyophilization, and aseptic processing with Grade A isolator-based technology for potent compounds, cytotoxics, hormones, and steroids.
  • Antibody Drug Conjugates (ADCs) End-to-end antibody-drug conjugate development and manufacturing including payload-linker development, conjugation, and fill-finish services across Grangemouth (UK), Riverview (USA), and Lexington (USA) sites. First FDA-approved ADC CDMO with 20+ years of experience and 1,500+ ADC batches manufactured.
  • ADCelerate Proprietary integrated ADC solution platform that accelerates timelines for developing initial clinical supply of both drug substance and drug product, covering preclinical to commercial-scale manufacturing via the ADCelerate program.
  • Peptides End-to-end peptide API development and manufacturing services including both solution phase and solid phase synthesis capabilities, regulatory filings, and characterization for commercial supply.
  • Vaccines and Biologics Development and manufacturing services for vaccines, gene therapy, monoclonal antibodies, and other complex biologics up to 1,000L scale, delivered through associate company Yapan Bio at the Hyderabad facility with BSL-2+ containment.
  • Nutrition Solutions Comprehensive nutrition solutions including human nutrition premixes (vitamin mineral, fortification, customized), animal nutrition products (Nicomix vitamin premix, liquid feed supplements), skincare ingredients (MaxReti retinol products), and food fortification programs.

Quantifiable outcome

  • Zero OAI observations across all USFDA inspections
  • +4 more outcomes

Companies that use Piramal Pharma Solutions

Customer profile

Named customers2 records

Segments1 record

Ideal customer profiles1 record

Piramal Pharma Solutions technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Piramal Pharma Solutions partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and supporting.

  • Botanix SB Inc.coreStrategic or Co-development Partner · 18 May 2026Manufacturing and supply agreement for Sofdra (sofpironium bromide), the first FDA-approved new chemical entity for treating primary axillary hyperhidrosis. PPS will perform development and validation at Riverview, Michigan with potential dual-source production at Aurora, Canada facility to provide supply chain redundancy and cost efficiencies. Partnership expected to significantly reduce Botanix's cost of goods sold while ensuring consistent patient access.
  • Ajinomoto Bio-Pharma ServicescoreStrategic or Co-development Partner · 16 April 2026Strategic collaboration to support ADC development and manufacturing. Piramal will refer ADC manufacturing customers to Ajinomoto's AJICAP technology platform while Ajinomoto will refer customers to Piramal for CDMO services. Companies entered Material Transfer Agreement enabling technology transfer for Piramal to manufacture AJICAP-based products. Combines Ajinomoto's site-specific conjugation technology with Piramal's clinical and commercial ADC GMP manufacturing expertise.
  • IntoCellsupportingStrategic or Co-development Partner · 30 October 2025Formalized partnership through Memorandum of Understanding to expand bioconjugate capabilities and ADC development services. Agreement involves exploring licensing of IntoCell's drug-linker technologies and offering contract research and manufacturing services.
  • Yapan BiocoreStrategic or Co-development PartnerAssociate company providing biologics and vaccine development and manufacturing services. Yapan Bio specializes in process development, scale-up, and GMP-compliant manufacturing of vaccines, gene therapy, monoclonal antibodies, and other complex biologics. Piramal leverages this partnership to offer integrated large molecule services.

Scale indicators14 records

Recent moves10 records

Expansion highlights4 records

Piramal Pharma Solutions competitors and assessment

Company assessment

Direct peers

  • Catalent: One of the largest pure-play CDMOs globally, offering integrated drug substance, drug product, biologics, and ADC capabilities. Direct competitor to Piramal across formulation, fill-finish, and biologics CDMO services.
  • Lonza: Global CDMO leader in biologics, small molecules, and cell & gene therapies. Comparable to Piramal in small-molecule API manufacturing and overlapping in sterile fill-finish and biologics CDMO.
  • Samsung Biologics: Major biologics CDMO with large-scale mammalian cell culture capacity. Overlaps with Piramal/Yapan Bio in biologics and vaccine contract manufacturing.
  • WuXi STA: Subsidiary of WuXi AppTec providing integrated API and drug product CDMO services. Direct overlap with Piramal's API manufacturing and formulation development offerings.
  • Recipharm: European-headquartered CDMO with strong sterile injectables and oral solids capabilities. Comparable to Piramal in drug product contract manufacturing and HPAPI handling.
  • Curia: Global CDMO offering integrated API and drug product services including HPAPIs and complex chemistry. Direct mid-tier CDMO competitor with overlapping capabilities to Piramal.

Broad incumbents

  • Thermo Fisher Scientific (CDMO / Patheon): Operates a large CDMO business via Patheon. Broader portfolio than Piramal but directly competes across API, drug product, and sterile injectable contract manufacturing.
  • Boehringer Ingelheim BioXcellence: Biologics CDMO division of Boehringer Ingelheim, providing process development and commercial manufacturing for biopharmaceuticals. Comparable to Piramal/Yapan Bio's biologics offering.
  • Eurofins CDMO: Eurofins' pharmaceutical CDMO operations offer API development and manufacturing services with global reach, comparable to Piramal's small-molecule API business.

Regional players

  • Syngene International: India-based CRO/CDMO providing discovery, development, and manufacturing services. Strong geographic and capability overlap with Piramal's India-based operations and integrated CDMO model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Piramal Pharma Solutions social profiles

Digital presence

Piramal Pharma Solutions compliance and trust

Trust signal

Compliance18 records

Piramal Pharma Solutions financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Piramal Pharma Solutions leadership team

Management profile

Number of profiles

Profiles9 records

Piramal Pharma Solutions subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Piramal Pharma Solutions funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Piramal Pharma Solutions M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Piramal Pharma Solutions

What does Piramal Pharma Solutions do?

Piramal Pharma Solutions is a global Contract Development and Manufacturing Organization (CDMO) that provides end-to-end pharmaceutical services across the drug lifecycle, from discovery through commercialization. Core offerings include drug discovery services (synthetic chemistry, in-vitro biology, DMPK), drug substance/API development and manufacturing (including high-potency, peptides, hormonal, and controlled substances), drug product formulation and manufacturing (oral solids, liquids, creams, ointments, sterile injectables), and specialized offerings in antibody drug conjugates (via the ADCelerate platform), vaccines and biologics, and nutrition solutions.

Is Piramal Pharma Solutions a public or private company?

Piramal Pharma Solutions is a private company. It is classified as corporate owned and is currently operating.

When was Piramal Pharma Solutions founded?

Piramal Pharma Solutions was founded in 1990. It employs 1,001 to 5,000 people.

Where is Piramal Pharma Solutions based?

Piramal Pharma Solutions is headquartered in Lexington, United States, in the North America region.

How does Piramal Pharma Solutions make money?

Four revenue lines are on record. Contract Development and Manufacturing (CDMO) Services are the primary driver. The others are API Manufacturing and Sales, drug Product Manufacturing and specialized Services.

Who are Piramal Pharma Solutions's main competitors?

Direct peers on record are Catalent, Lonza, Samsung Biologics, WuXi STA, Recipharm and Curia. Broad incumbents are Thermo Fisher Scientific (CDMO / Patheon), Boehringer Ingelheim BioXcellence and Eurofins CDMO. Syngene International is listed as a regional player.

Does Piramal Pharma Solutions have an API?

No public API is recorded for Piramal Pharma Solutions.

What industry is Piramal Pharma Solutions in?

Piramal Pharma Solutions's product category is Pharmaceutical Contract Development and Manufacturing Organization (CDMO). Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The TribunePiramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable FacilityPiramal Pharma Solutions opened a new microbiology laboratory and sterility testing suite at its Lexington, Kentucky sterile injectable facility on September 11, 2026. The addition triples the site's microbiology testing space and doubles sterility testing capacity, with the full $85 million expansion expected online in late 2027.PR Newswire APAC/C O R R E C T I O N -- Piramal Pharma Solutions/Piramal Pharma Solutions opened a new microbiology laboratory at its Lexington, Kentucky sterile injectable facility, released for GMP use on September 11, 2026. The lab triples testing space and doubles sterility testing capacity, with the full $85 million expansion expected operational in late 2027.The TribunePiramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable FacilityPiramal Pharma Solutions opened a new microbiology laboratory at its Lexington, Kentucky sterile injectable facility, released for GMP use on September 11, 2026. The lab triples existing microbiology space and includes a Grade A sterility testing isolator, with full expansion expected operational in late 2027.PR Newswire APACPiramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable FacilityPiramal Pharma Solutions opened a new microbiology laboratory and sterility testing suite at its Lexington, Kentucky sterile injectable facility on September 11, 2026. The lab triples existing microbiology space and doubles sterility testing capacity, with full expansion expected in late 2027.Business StandardPiramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable FacilityPiramal Pharma Solutions opened a new microbiology laboratory and sterility testing suite at its Lexington, Kentucky sterile injectable facility on September 11, 2026. The lab triples existing microbiology space and doubles sterility testing capacity, with full expansion expected in late 2027.Financial PostPiramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable FacilityPiramal Pharma Solutions opened a new microbiology laboratory and sterility testing suite at its Lexington, Kentucky sterile injectable facility on September 11, 2026. The addition triples the site's microbiology testing space and doubles sterility testing capacity, with the full $85 million expansion expected online in late 2027.PR NewswirePiramal Pharma Solutions eröffnet ein neues mikrobiologisches Labor in seiner Produktionsstätte für sterile Injektionspräparate in Lexington, KentuckyPiramal Pharma Solutions opened a new microbiology lab at its Lexington, Kentucky sterile injectable site, expanding the area by over three times. The lab adds three biosafety cabinets and a Class A isolator, cutting test times by up to 50% and doubling sterility testing capacity.PR NewswirePiramal Pharma Solutions inaugure un nouveau laboratoire de microbiologie dans son site de fabrication de produits injectables stériles de Lexington, dans le KentuckyPiramal Pharma Solutions inaugurated a new microbiology laboratory at its Lexington, Kentucky sterile injectables manufacturing site, tripling the space dedicated to microbiological analyses. The lab includes three new biosafety cabinets and a class A sterility control isolator, aiming to cut sterility test durations by 50% and support future commercial demand.PR NewswirePiramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable FacilityPiramal Pharma Solutions opened a new microbiology laboratory at its Lexington, Kentucky sterile injectable facility, released for GMP use on September 11, 2026. The lab triples testing space and doubles sterility testing capacity, with full expansion expected operational in late 2027.PR NewswirePiramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable FacilityPiramal Pharma Solutions opened a new microbiology laboratory at its Lexington, Kentucky sterile injectable facility, released for GMP use on September 11, 2026. The lab triples testing space and doubles sterility testing capacity, with full expansion expected operational in late 2027.